




TBS Reveal. One step ahead of osteoporosis

AI-driven opportunistic bone fragility assessment from routine X-rays

Osteoporosis: the silent risk you can now see

Osteoporosis quietly weakens bone density and bone microarchitecture, often going undiagnosed until a fracture occurs. More than 70% of patients with fragility fractures are never tested or treated for osteoporosis¹, leaving millions at risk and driving up healthcare costs.

TBS Reveal* closes this gap.

Turn routine X-rays into early insights with TBS Reveal



Identify patients with high bone fragility by assessing combined bone mass (BMD) and bone microarchitecture (TBS).



Proactive early detection with AI-powered opportunistic screening that analyzes routine X-rays to detect bone fragility early and efficiently. No dedicated imaging required.



Flag when it matters by using sustainable AI model optimized to highlight those at highest risk — supporting accurate detection and efficient resource use.




Support inclusive care by extending bone fragility assessment beyond traditional risk groups, from age 20 upward.

Zero workflow disruption, tailored to your needs

Seamlessly integrated with the PACS, TBS Reveal can automatically generate a Bone Fragility Assessment report.


- **One click:** access results in the same patient series.
- **No additional radiation.**
- **Smart reporting:** control frequency, tags, and scan selection.
- **Auto or manual:** automatic or manual scan analysis.
- **Flexible setup:** built for diverse IT environments.



1. Compston 2020; Bluic et al., 2021

* TBS Reveal is now CE marked under MDR and pending 510k approval

See more. Detect earlier. Treat smarter



AI-driven Bone Fragility Assessment report for clinicians

Instantly accessible for timely, informed decisions.



The report provides:

- **Trabecular Bone Score (TBS):** a measure of bone quality microarchitecture.
- **Bone Fragility Index:** combines TBS and bone mass (BMD) into one indicator.
- **AI Heatmap:** visual overlay highlighting areas of bone fragility.
- **DICOM:** secondary capture and structured report options.

Clinically validated. AI-driven

TBS Reveal has been evaluated across an average of 18,500 paired patient datasets from independent, international cohorts. Optimized for specificity, TBS Reveal delivers reliable results that fit the needs of modern radiology.²

AUC	Accuracy	Specificity
84%	90%	94%
Accurately distinguishes patients with and without bone fragility.	9 out of 10 results correctly predict the patient's bone status.	Confident exclusion of false positives.



Book a demo and discover how you can **reveal more and care smarter**



MEDIMAPS

We understand bone health

Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment.

Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA.

For more information, please visit our website www.medimaps.ai © 2026 Medimaps Group. MM-BR-1341-MIG-EN-01--WW. TBS Reveal is a trademark of Medimaps Group. Not all products are available in all global markets. Please refer to your local distributor or agent. Medimaps Group reserves the right to modify the specifications and features described herein or discontinue manufacture of the product described at any time without prior notice or obligation. Please contact your authorized Medimaps representative for the most updated information. Medimaps Group has been certified by BSI to ISO 13485:2016 under certificate number MD 79972. TBS Reveal is now CE marked under MDR and pending 510k approval.